A Panoply of Rheumatological Manifestations in Patients with GATA2 Deficiency.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
20 05 2020
Historique:
received: 31 01 2020
accepted: 23 04 2020
entrez: 21 5 2020
pubmed: 21 5 2020
medline: 15 12 2020
Statut: epublish

Résumé

To characterize rheumatological manifestations of GATA2 deficiency. Single-center, retrospective review of 157 patients with GATA2 deficiency. Disease course, laboratory results, and imaging findings were extracted. In-person rheumatological assessments were performed on selected, available patients. A literature search of four databases was conducted to identify additional cases. Rheumatological findings were identified in 28 patients, out of 157 cases reviewed (17.8%). Twenty-two of those patients (78.6%) reported symptom onset prior to or in conjunction with the molecular diagnosis of GATA2 deficiency. Notable rheumatological manifestations included: piezogenic pedal papules (PPP), joint hyperextensibility, early onset osteoarthritis, ankylosing spondylitis, and seronegative erosive rheumatoid arthritis. In peripheral blood of patients with rheumatological manifestations and GATA2 deficiency, CD4+ CD3+ helper T cells and naïve CD3+ CD4+ CD62L+ CD45RA+ helper T cell subpopulation fractions were significantly lower, while CD8+ cytotoxic T cell fractions were significantly higher, compared to those without rheumatological manifestations and with GATA2 deficiency. No changes in CD19, CD3, or NK populations were observed. GATA2 deficiency is associated with a broad spectrum of rheumatological disease manifestations. Low total helper T lymphocyte proportions and low naïve helper T cell proportions are associated with those most at risk of overt rheumatological manifestations. Further, PPP and joint hyperextensibility may explain some of the nonimmunologically-mediated joint problems encountered in patients with GATA2 deficiency. This catalogue suggests that rheumatological manifestations and immune dysregulation are relatively common in GATA2 deficiency.

Identifiants

pubmed: 32433473
doi: 10.1038/s41598-020-64852-1
pii: 10.1038/s41598-020-64852-1
pmc: PMC7239896
doi:

Types de publication

Journal Article Research Support, N.I.H., Intramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

8305

Références

Spinner, M. A. et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood 123, 809–821 (2014).
doi: 10.1182/blood-2013-07-515528
Donadieu, J. et al. Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. haematologica 103, 1278–1287 (2018).
doi: 10.3324/haematol.2017.181909
Mace, E. M. & Orange, J. S. Emerging insights into human health and NK cell biology from the study of NK cell deficiencies. Immunological reviews 287, 202–225 (2019).
doi: 10.1111/imr.12725
Cuellar-Rodriguez, J. et al. Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Blood 118, 3715–3720, https://doi.org/10.1182/blood-2011-06-365049 (2011).
doi: 10.1182/blood-2011-06-365049 pubmed: 21816832 pmcid: 3186343
Johnson, J. A., Yu, S. S., Elist, M., Arkfeld, D. & Panush, R. S. Rheumatologic manifestations of the “MonoMAC” syndrome. a systematic review. Clinical Rheumatology 34, 1643–1645, https://doi.org/10.1007/s10067-015-2905-2 (2015).
doi: 10.1007/s10067-015-2905-2 pubmed: 25739845
Vinh, D. C. et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 115, 1519–1529 (2010).
doi: 10.1182/blood-2009-03-208629
Bigley, V. & Matthew, C. Dendritic cell, monocyte, B and NK lymphoid deficiency defines the lost lineages of a new GATA-2 dependent myelodysplastic syndrome. Haematologica, 1081–1083 (2011).
Bigley, V. et al. The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency. Journal of Experimental Medicine 208, 227–234 (2011).
doi: 10.1084/jem.20101459
Ishida, H. et al. GATA-2 anomaly and clinical phenotype of a sporadic case of lymphedema, dendritic cell, monocyte, B- and NK-cell (DCML) deficiency, and myelodysplasia. European Journal of Pediatrics 171, 1273–1276, https://doi.org/10.1007/s00431-012-1715-7 (2012).
doi: 10.1007/s00431-012-1715-7 pubmed: 22430350
Camargo, J. F. et al. MonoMAC syndrome in a patient with a GATA2 mutation: Case report and review of the literature. Clinical Infectious Diseases 57, 697–699, https://doi.org/10.1093/cid/cit368 (2013).
doi: 10.1093/cid/cit368 pubmed: 23728141 pmcid: 3739466
Prader, S. et al. Life-threatening primary varicella zoster virus infection with hemophagocytic lymphohistiocytosis-like disease in GATA2 haploinsufficiency accompanied by expansion of double negative T-lymphocytes. Frontiers in immunology 9, 2766 (2018).
doi: 10.3389/fimmu.2018.02766
Polat, A. et al. Skin manifestations among GATA2-deficient patients. British Journal of Dermatology 178, 781–785, https://doi.org/10.1111/bjd.15548 (2018).
doi: 10.1111/bjd.15548 pubmed: 28440875
Damian, L. et al. Pseudo-Sarcoidosis Revealing MonoMAC Syndrome. Journal of Clinical Immunology 38, 739–741, https://doi.org/10.1007/s10875-018-0551-6 (2018).
doi: 10.1007/s10875-018-0551-6 pubmed: 30280306
Dickinson, R. E. et al. The evolution of cellular deficiency in GATA2 mutation. Blood 123, 863–874 (2014).
doi: 10.1182/blood-2013-07-517151
Ringold, S. et al. American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non‐systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis care & research 71, 717–734 (2019).
doi: 10.1002/acr.23870
Silva, B. C. & Leslie, W. D. Trabecular bone score: a new DXA–derived measurement for fracture risk assessment. Endocrinology and Metabolism Clinics 46, 153–180 (2017).
doi: 10.1016/j.ecl.2016.09.005
Han, X., Boyd, P. J., Colgan, S., Madri, J. A. & Haas, T. L. Transcriptional up-regulation of endothelial cell matrix metalloproteinase-2 in response to extracellular cues involves GATA-2. Journal of Biological Chemistry 278, 47785–47791 (2003).
doi: 10.1074/jbc.M309482200
Rastogi, A., Kim, H., Twomey, J. D. & Hsieh, A. H. MMP-2 mediates local degradation and remodeling of collagen by annulus fibrosus cells of the intervertebral disc. Arthritis research & therapy 15, R57 (2013).
doi: 10.1186/ar4224
Tolkachov, A. et al. Loss of the Hematopoietic Stem Cell Factor GATA2 in the Osteogenic Lineage Impairs Trabecularization and Mechanical Strength of Bone. Mol Cell Biol 38, https://doi.org/10.1128/mcb.00599-17 (2018).
Wei, W. et al. Osteoclast progenitors reside in the peroxisome proliferator-activated receptor gamma-expressing bone marrow cell population. Mol Cell Biol 31, 4692–4705, https://doi.org/10.1128/mcb.05979-11 (2011).
doi: 10.1128/mcb.05979-11 pubmed: 21947280 pmcid: 3232921
Wei, W. et al. Biphasic and dosage-dependent regulation of osteoclastogenesis by beta-catenin. Mol Cell Biol 31, 4706–4719, https://doi.org/10.1128/mcb.05980-11 (2011).
doi: 10.1128/mcb.05980-11 pubmed: 21876000 pmcid: 3232928
Moos, S., Mohebiany, A. N., Waisman, A. & Kurschus, F. C. Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes. Journal of Investigative Dermatology 139, 1110–1117 (2019).
doi: 10.1016/j.jid.2019.01.006
Machler, B., Mark, N., Patel, U. & Levine, V. Imiquimod induced psoriasis: A case report, review of the literature, and pathophysiologic mechanism: P3313. Journal of the American Academy of Dermatology 64 (2011).
Bugault, F. et al. Altered responses to homeostatic cytokines in patients with idiopathic CD4 lymphocytopenia. PloS one 8, e55570 (2013).
doi: 10.1371/journal.pone.0055570
Wehr, C. et al. A new CD21low B cell population in the peripheral blood of patients with SLE. Clinical immunology 113, 161–171 (2004).
doi: 10.1016/j.clim.2004.05.010
Thorarinsdottir, K. et al. CD 21‐/low B cells associate with joint damage in rheumatoid arthritis patients. Scandinavian journal of immunology, e12792 (2019).
Saadoun, D. et al. Expansion of autoreactive unresponsive CD21−/low B cells in Sjögren’s syndrome–associated lymphoproliferation. Arthritis & Rheumatism 65, 1085–1096 (2013).
doi: 10.1002/art.37828
Illges, H., Braun, M., Peter, H. & Melchers, I. Reduced expression of the complement receptor type 2 (CR2, CD21) by synovial fluid B and T lymphocytes. Clinical & Experimental Immunology 122, 270–276 (2000).
doi: 10.1046/j.1365-2249.2000.01379.x
Yeo, L. et al. Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis. Annals of the rheumatic diseases 74, 928–935 (2015).
doi: 10.1136/annrheumdis-2013-204116
Mensah, K. A. et al. Impaired ATM activation in B cells is associated with bone resorption in rheumatoid arthritis. Science Translational Medicine 11 (2019).
Grant, C. R., Liberal, R., Mieli-Vergani, G., Vergani, D. & Longhi, M. S. Regulatory T-cells in autoimmune diseases: challenges, controversies and—yet—unanswered questions. Autoimmunity reviews 14, 105–116 (2015).
doi: 10.1016/j.autrev.2014.10.012

Auteurs

Abhimanyu A Amarnani (AA)

Office of the Clinical Director, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA. aamarnan@usc.edu.
SUNY Downstate Health Sciences University, College of Medicine and School of Graduate Studies, Brooklyn, USA. aamarnan@usc.edu.
Department of Medicine, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA. aamarnan@usc.edu.

Katlin R Poladian (KR)

Office of the Clinical Director, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Beatriz E Marciano (BE)

National Institute of Allergy and Infectious Diseases, Intramural Research Program, National Institutes of Health, Bethesda, Maryland, USA.

Janine R Daub (JR)

National Institute of Allergy and Infectious Diseases, Intramural Research Program, National Institutes of Health, Bethesda, Maryland, USA.

Sandra G Williams (SG)

Office of the Clinical Director, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Alicia A Livinski (AA)

National Institutes of Health Library, Division of Library Services, Office of Research Services, OD, NIH, Bethesda, Maryland, USA.

Amy P Hsu (AP)

National Institute of Allergy and Infectious Diseases, Intramural Research Program, National Institutes of Health, Bethesda, Maryland, USA.

Cindy L Palmer (CL)

National Institute of Allergy and Infectious Diseases, Intramural Research Program, National Institutes of Health, Bethesda, Maryland, USA.

Cara M Kenney (CM)

National Cancer Institute, Center for Cancer Research, Office of the Clinical Director, National Institutes of Health, Bethesda, Maryland, USA.

Daniele N Avila (DN)

National Cancer Institute, Center for Cancer Research, Office of the Clinical Director, National Institutes of Health, Bethesda, Maryland, USA.

Steven M Holland (SM)

National Institute of Allergy and Infectious Diseases, Intramural Research Program, National Institutes of Health, Bethesda, Maryland, USA.

James D Katz (JD)

Office of the Clinical Director, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH